Abstract 3248
Background
Metastatic esophagogastric cancer patients can be treated with paclitaxel/ramucirumab, or another taxane, or an irinotecan-containing regimen in second line. The aim of this study was to explore the real-world use of second-line palliative systemic treatment in esophagogastric cancer and to compare treatment regimens in terms of overall survival (OS) and time to failure of second-line treatment (TTF).
Methods
Synchronous metastatic esophagogastric cancer patients treated with systemic therapy (2010-2015) were selected from the nationwide Netherlands Cancer Registry. Systemic treatment was considered second line if a drug group was used that essentially differed from first-line treatment, irrespective of reason for switch of treatment. Thus, a switch from capecitabine/oxaliplatin (CapOx) to docetaxel was considered second line, while CapOx to i.v. 5-fluorouracil (5-FU)/oxaliplatin was not. OS and TTF were calculated from start of second-line treatment until date of death, or progression/failure of treatment, and analyzed using Kaplan Meier curves with logrank test.
Results
Second-line systemic treatment was applied in 344 (20%) of the 1712 patients that received first-line systemic treatment in 2010-2015, of which 96% had adenocarcinoma and 4% squamous cell carcinoma. In the total cohort, 38 different second-line systemic treatment regimens were administered. Monotherapy with a taxane (31%), paclitaxel/ramucirumab (13%), carboplatin/paclitaxel (10%), trastuzumab-containing regimens (7%), fluoropyrimidine/platinum doublets (7%), irinotecan (6%), and 5-FU/irinotecan (6%) were most frequently used regimens. In patients that received second-line treatment, median OS was 5.2 (IQR 2.7, 8.6) and TTF 2.8 (IQR 1.5, 5.0) months. Median OS was 3.9 (IQR 2.3, 6.4) months in patients treated with second-line taxane monotherapy (n = 108), and 5.4 (IQR 2.3, 9.7) months in patients treated with paclitaxel/ramucirumab (n = 45, p = 0.188).
Conclusions
According to real-world evidence, 20% of synchronous metastatic esophagogastric cancer patients treated with first-line systemic therapy receive second-line systemic treatment, most frequently consisting of a taxane with or without ramucirumab.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Lilly.
Disclosure
R.H.A. Verhoeven: Research grant / Funding (institution): Roche; Research grant / Funding (institution): BMS. N. Haj Mohammad: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD. J. de Vos-Geelen: Non-remunerated activity/ies: BTG; Research grant / Funding (institution), Non-remunerated activity/ies: Servier; Advisory / Consultancy: Shire. T. Van Voorthuizen: Non-remunerated activity/ies: Astellas; Non-remunerated activity/ies: Ipsen; Non-remunerated activity/ies: Roche; Non-remunerated activity/ies: Bayer. M. van Oijen: Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Nordic; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Roche. H.W.M. van Laarhoven: Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Nordic; Research grant / Funding (institution): Philips; Research grant / Funding (institution): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2670 - Molecular subtypes of metastatic(met) gastric cancer(GC) (MoTriGastric): new biomarkers closer to the clinics
Presenter: Maria Alsina Maqueda
Session: Poster Display session 2
Resources:
Abstract
3797 - Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer
Presenter: Aafke Creemers
Session: Poster Display session 2
Resources:
Abstract
5485 - Clinical implication of CLDN18, RhoGAP, and E-cadherin in gastric signet ring cell carcinoma
Presenter: Hyunho Kim
Session: Poster Display session 2
Resources:
Abstract
1970 - Identification of a spectrum of germline mutations for hereditary diffuse gastric cancer in the Russian population by next-generation sequencing.
Presenter: IRINA EFIMOVA
Session: Poster Display session 2
Resources:
Abstract
4989 - The molecular profiling and prognostic value of Chinese gastric signet ring cell carcinoma patients
Presenter: Jia Wei
Session: Poster Display session 2
Resources:
Abstract
7145 - A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
Presenter: Alison Schram
Session: Poster Display session 2
Resources:
Abstract
1406 - Simultaneous Resection of Pancreatic Cancer and Liver Oligometastases After Induction Chemotherapy in Stage IV Patients:an Open-Label Prospective Randomized Multicenter phase 3 trial(CSPAC-1)
Presenter: Miaoyan Wei
Session: Poster Display session 2
Resources:
Abstract
1530 - Multicenter randomized phase II trial of 5-Fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial
Presenter: Changhoon Yoo
Session: Poster Display session 2
Resources:
Abstract
1563 - A randomized phase II study of Maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced Pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)
Presenter: Cindy Neuzillet
Session: Poster Display session 2
Resources:
Abstract
2780 - A phase 3, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Presenter: Do-Youn Oh
Session: Poster Display session 2
Resources:
Abstract